Nimodipine Altan Pharma (Nimodipine)

Nimodipine selectively blocks L‑type calcium channels on the smooth muscle of cerebral vessels. This inhibition reduces calcium‑mediated contraction, leading to vasodilation of intracranial arteries and a decrease in vascular resistance, which mitigates vasospasm.

The dosing regimen for Nimodipine Altan Pharma is determined by the prescribing clinician based on the patient’s condition, weight, and response. Healthcare professionals set the appropriate infusion rate and duration according to clinical guidelines.

Safety data for Nimodipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Nimodipine is a dihydropyridine calcium channel blocker with high selectivity for cerebral vessels, offering a favorable safety profile compared with non‑selective vasodilators. Its ability to cross the blood‑brain barrier makes it particularly effective for preventing vasospasm after subarachnoid hemorrhage.

Store the product at temperatures below 25 °C, in its original container, protected from moisture and light. Do not freeze. Follow standard aseptic handling procedures for intravenous preparations to maintain sterility.

Nimodipine Altan Pharma is administered intravenously under the supervision of a qualified healthcare professional. The infusion is typically given over a defined period, with continuous monitoring of blood pressure and cardiac status throughout the administration.

The most serious risks include severe hypotension, bradycardia, allergic reactions such as anaphylaxis, and rare hepatic toxicity. Prompt recognition and management of these events are essential, and patients should be monitored closely during therapy.

Patients with known hypersensitivity to nimodipine or other dihydropyridine calcium channel blockers should avoid the drug. Caution is also advised for individuals with severe hypotension, advanced heart block, or significant liver impairment, and the decision should be made by a physician.